Qualyst.com is under construction

BCLEAR_Correlation_graph_7316.jpg

Fluorescent image of 5,(6)-carboxy-2',7'dichlorofluorescein (CDF) in B-CLEAR® RT. The proportion of CDF found in the bile canaliculi (biliary excretion index) is approximately 35% and in vitro  biliary clearance is approximately 8.2 mL/min/kg body mass.

Probe substrates using B-CLEAR® demonstrate a high in vitro to in vivo biliary clearance correlation in both rat and human studies.


B-CLEAR®, a patented* and Transporter Certified sandwich-cultured hepatocyte platform, is the only in vitro method to predict in vivo hepatic uptake, biliary excretion, and biliary clearance. B-CLEAR® is the only system with certified uptake AND efflux transport.

B-CLEAR® allows you to:




Qualyst's mission is to develop and deliver quality products and data to clients based on our industry-leading expertise in drug transport and hepatic disposition.

bile_ducts_8535.jpg

© Copyright 2011-2012 Qualyst, Inc. All Rights Reserved.

B-CLEAR® is a registered trademark of Qualyst, Inc.

*B-CLEAR® is covered by US Patent 6,780,580 and other worldwide patents issued & pending.


Qualyst_Co_logo.jpgHome_page_graphic_2477.jpg


Transporter Certified means that the specified product has been functionally evaluated for multiple uptake and efflux transporters and that the values determined fall within a defined range of acceptable values.




The International Transporter Consortium recognizes the importance
of the sandwich-cultured hepatocyte model in drug development (Nat Rev Drug Discov. 2010 Mar;9(3):215-36). Read our article on drug transport and the utility of
B-CLEAR® in drug discovery and development here.
banner_9141.jpgbanner_9141.jpg